



(12) UK Patent (19) GB (11) 2 190 587 (13) B

(54) Title of invention

Prophylactic and curing composition for arteriosclerosis

(51) INT CL⁴; A61K 31/55 ✓

(21) Application No
8711752.9

(22) Date of filing
19 May 1987

(30) Priority data

(31) 61119928

(32) 23 May 1986

(33) JP

(43) Application published
25 Nov 1987

(45) Patent published
17 Jan 1990

(73) Proprietor(s)
Tanabe Seiyaku Co Ltd

(Incorporated in Japan)

2-10 Dosho-machi 3-chome
Chuo-ku
Osaka
Japan

(72) Inventor(s)
Hitoshi Iwasaki
Kitamura Kitamura
Akio Ohtani

(74) Agent and/or
Address for Service
Boult, Wade & Tennant
27 Fumival Street
London EC4A 1PQ

(52) Domestic classification
(Edition J)
A5B BHA B180 B44Y B443
B47Y B471 B48Y B480 B482
B50Y B503 B55Y B556 B57Y
B577 B58Y B586 B61Y B616
B65Y B650
U1S S2415

(56) Documents cited
EP 0127882 A1
US 4567175 A

(58) Field of search

As for published application
2190587 A viz:
UK CL A5B
INT CL⁴ A61K
updated as appropriate

PROPHYLACTIC AND CURING COMPOSITION FOR
ARTERIOSCLEROSIS

5 The present invention relates to a novel use of
an 8-chlorobenzothiazepine compound for preparing
prophylactic or curing medicament. 2-(4-
methoxyphenyl)-3-alkanoyloxy-5-[2-(dialkylamino)ethyl]-
8-chloro-2,3-dihydro-1,5-benzothiazepine-4(5H)-one is
10 a known compound, and excellent hypotensive activity
and/or cerebral and coronary vasodilating activity
Japanese Unexamined Patent Publication No.
225174/1984 and United States Patent Specification
No. 4567175.

15 However, in the prior art, it has not been
known previously that this compound shows
anti-arteriosclerosis activity.

20 Arteriosclerosis is pathologically classified into
the three groups of atherosclerosis, Mönkeberg's sclerosis
(medial sclerosis) and arteriolosclerosis. Atherosclero-
sis is characterized by lipid deposition and plaque forma-
tion in the intima of e.g., coronary artery, basilar
25 artery, renal artery, thoracic aorta or abdominal aorta.
Mönkeberg's sclerosis is frequently observed in medium-
sized arteries in extremities, such as e.g., femoral
artery, and characterized by calcification of arterial
media. Arteriolosclerosis is a sclerotic change which is

30

35

observed in arterioles in e.g. the kidney, adrenal gland, spleen, ovary or pancreas.


In recent years, advanced studies have been made about these arterioscleroses, and it has been considered that non-limited growth of medial smooth muscle cells in the intima of blood vessels and abnormal accumulation of cholesterol within cells can be the causes for such arteriosclerosis, and the relationship between such causes and prostacyclin (PGI_2) is now of interest. For example, when a rabbit is fed with a cholesterol-rich diet, it has been known that prostacyclin-producing ability of artery is lowered together with the progress of arteriosclerosis of said rabbit.

It is also known that prostacyclin-producing ability is lowered at the arteriosclerotic lesion site to a level half or lower of that at normal site [Gendai Iryo (Modern Medical Treatment), 12, 909(1980)].

On the other hand, Hajjar et al report that addition of prostacyclin to a culture system of medial smooth muscle cells from rabbit aorta increases ACEH (Acid cholesteryl ester hydrolase) activity of the cells, whereby deposition of cholesterol within cells is inhibited [Journal of Clinical Investigation, 70, 479 (1982)]. Further, it is also reported for medial smooth muscle cells from arteriosclerotic lesions that addition of prostacyclin in a culture system lowers the cholesterol content in said cells [Lancet, 2, 521 (1983)].

The present invention, in view of the state of the art as described above, is concerned with novel prophylactic and curing agent for arteriosclerosis having the activity of potentiating prostacyclin producing ability of medial smooth muscle cells of blood vessel and also having anti-arteriosclerosis activity.

According to the present invention there is provided the use of an 8-chloro-1,5-benzothiazepine derivative represented by the formula:



15 wherein R^1 , R^2 , R^3 and R^4 each represent alkyl groups having from 1 to 6 carbon atoms of an acid addition salt thereof, for the preparation of a prophylactic or curing medicament for arteriosclerosis.

20 As the compound (I) which is the active ingredient of the present invention, there may be included compounds wherein R^1 , R^2 , R^3 and R^4 in the above formula are lower alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group or a hexyl group.

25 Since these compounds have two asymmetric carbons in the molecule, there exist two kinds of stereoisomers (namely cis- and trans-isomers) or 4 kinds of optical isomers (namely, (+)-cis, (-)-cis, (+)-trans and (-)-trans-isomers), and the present invention is inclusive of

30

35

all of these respective isomers and their mixtures.

However, generally speaking, cis-isomers are preferred as pharmaceuticals.

5 The compound (I) which is the active ingredient of the present invention potentiates markedly the prostacyclin-producing ability of medial smooth muscle cells of blood vessels and also has excellent anti-arteriosclerosis activity.

10 For example, when (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one was added to cultured rat aortic smooth muscle cells for examination of prostacyclin producing ability of said cells, the above compound exhibited excellent activity for potentiating prostacyclin
15 producing ability. Also, when the effect of (+)-cis-2-(4-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one for experimental atherosclerosis in rabbits and Mönkeberg's sclerosis in rats were examined, the above compound exhibited
20 excellent ameliorating effect on either type of arteriosclerosis. Thus, the medicament of the present invention can be used for prophylaxis or treatment of various arteriosclerosis such as atherosclerosis, Mönkeberg's sclerosis (medial sclerosis) and arteriolosclerosis.

25 The above compound (I) which is the active ingredient in the medicament of the present invention can be used for pharmaceutical uses in the form of either a free base or a pharmaceutically acceptable acid addition salt thereof. Examples of such pharmaceutically acceptable
30 acid addition salts may include inorganic acid addition salts such as hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate or phosphate or organic acid addition salts such as oxalate, maleate, fumarate, succinate, tartrate, methanesulfonate or 2-(4-hydroxybenzoyl) benzoate.

35 The compound (I) or a pharmaceutically acceptable

acid addition salt thereof can be administered both orally and parenterally together with excipients suitable for oral or parenteral administration. The medicament of the present invention can be formed ~~into a suitable preparation~~
5 ~~tion~~ by use of pharmaceutical carriers conventionally used in either oral or parenteral administration. Such pharmaceutical carriers may include, for example, binding agents (syrup, gum arabic, gelatin, sorbitol, tragacanth gum, polyvinylpyrrolidone, etc.), excipients (lactose, sucrose,
10 corn starch, potassium phosphate, sorbitol, glycine, etc.), lubricants (magnesium stearate, talc, polyethylene glycol, silica, etc.), disintegrators (potato starch, etc.) and wetting agents (sodium laurylsulfate, etc.). Preparation forms may be, e.g., tablets, pills, powders,
15 capsules or granules. Further, for parenteral administration, the medicament may be used in the form of an injection or instillation by use of distilled water for injection, physiological saline, aqueous glucose solution, etc., and also in the form a suspension, dispersion or
20 emulsion which is prepared with the use of glycerine, propylene glycol, simple syrup, ethanol, fatty oils, ethylene glycol or sorbitol.

The dose of the compound (I) or its acid addition salt which is the active ingredient of the present invention may vary according to the age and body weight of the
25 patient and the kind and severity of the disease, but is generally about 0.05 to 60 mg/kg/day, preferably about 0.05 to 10 mg/kg/day, particularly preferably 0.5 to 10 mg/kg/day in the case of oral administration and about
30 0.05 to 2 mg/kg/day in the case of parenteral administration.

The compound (I) which is the active ingredient of the present invention can be prepared according to, for example, the method disclosed in Japanese Unexamined
35 Patent Publication No. 225174/1984 (which corresponds to U.S. Patent No. 4,567,175).

Throughout the specification and claims, the term "lower alkyl" should be interpreted as referring to alkyl of one to 6 carbon atoms.

5

EXAMPLES

The present invention is described in more detail by referring to the following Experimental examples and Examples.

10

Experimental example 1

(Prostacyclin production promoting activity for aortic smooth muscle cells)

15

After rat aortic smooth muscle cells (hereinafter called SMC) were grown to confluence in culture dish by using growth medium, the growth medium was removed and preincubation was conducted with addition of a medium for assay at 37 °C for 15 minutes. Then, the medium was removed and a medium for assay containing a test compound was freshly added, followed by cultivation at 37 °C in 5 % CO₂ - 95 % air for 24 hours.

20

After completion of the cultivation, the prostacyclin production promoting activity of the test compound was examined by assaying the stable prostacyclin metabolite (6-KetoPGF₁α) existing in the supernatant according to radioimmunoassay. As the test compound, (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate was employed.

25

(Note) The respective media used in the above experiment had the following compositions.

30

Growth medium for proliferation: Eagle's Minimum Essential Medium + 10 % fetal calf serum
Medium for assay: Eagle's Minimum Essential Medium + 10 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfinic acid (pH 7.4)

35

<Results>

The results are shown in the following Table 1. It was recognized that the prostacyclin producing ability was increased to about 1.8-fold in the case of adding the test compound as compared with the case of no addition.

Table 1

Concentration of test compound added	Amount of 6-KetoPGF ₁ α produced (pg/24h x 10 ⁶ cells)
No addition	129 \pm 20
1 x 10 ⁻⁵ M	226 \pm 32

Experimental example 2

(Effect on atherosclerosis)

Rabbits (male, weight: about 2.4 Kg, one group: 10 rabbits) were fed with a lipid-rich diet (prepared by adding cholesterol (0.5 %) and soybean oil (3 %) to normal diet) for 12 weeks.

On the other hand, in order to examine the effect of the test compound on the arteriosclerosis in the aorta induced under such experimental conditions, an aqueous solution of the test compound (30 mg/kg) was administered to the animals with a stomach tube once a day at a fixed time simultaneously with initiation of dieting with the lipid-rich diet. Twelve weeks after initiation of the experiment, rabbits were killed under anesthesia (ether and pentobarbital were used in combination), and the proportion of the atheroma in the intima of the aortic arch and thoracic aorta (atheroma formation ratio) was examined.

As the test compound, (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate was used.

<Results>

The results are shown in Table 2, and it can be clearly seen that in the group administered the test compound atheroma formation ratio is lower as compared with that in the non-administration group.

This effect in the group administered the test compound suggests that the atheromatous changes, namely deposition of cholesterol in the blood vessel wall, atheroma formation accompanied with an increase in connective tissue filters in the intima and subsequent ulcer formation by breaks of said atheroma, are inhibited by the prostacyclin production potentiating effect of the compound of the present invention.

Table 2

	Atheroma formation rate (%)
Test compound non-administration group	51.2 ± 5.6
Test compound administration group	38.4 ± 5.8

Experimental example 3

(Effect on Mönkeberg's sclerosis)

Spontaneously hypertensive rats (male, age: 12 weeks, one group: 14 - 15 rats) were fed with a lipid-rich diet (prepared by adding cholesterol (3 %), hydrogenated cotton seed oil (7 %), cholic acid (0.5 %) and thiouracil (0.3 %) to normal diet) for 7 days, and further, for first four days, vitamin D₂ (8 mg/kg) was administered to the animals with a stomach tube in the form of a solution in olive oil (2 ml/kg) once at a fixed time every day. In order

to examine the effect of the test compound on Mönkeberg's sclerosis of the aorta induced under such experimental conditions, an aqueous solution of the test compound was administered to the animals with a stomach tube one hour and 7 hours after the administration of vitamin D₂ for 4 days, and further administration of the test compound alone was continued twice per day for the next 3 days.

On the 7th day after initiation of the experiment, the rats were killed under ether anesthesia and the lesions were examined.

As the test compound (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate was used.

<Results>

The results are shown in Table 3, and it can be clearly seen that the incidence of lesions is lowered in the group treated with the test compound.

Table 3

Lesions	Dose of test compound	
	0	30mg x 2/kg/day
Subdural hemorrhage	11/14	8/15
Periaortic hemorrhage	7/14	3/15
Subcutaneous hemorrhage	7/14	3/15

(In the numerical values in the Table, denominator indicates the number of rats used in the experiment, and numerator the number of rats in which lesions were recognized.)

Example 1

(Tablet)

5	(+)-Cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate	45.0 g
	Corn starch	20.1 g
	Lactose	82.4 g
	Polyvinylpyrrolidone	3.0 g
10	Crystalline cellulose	38.0 g
	<u>Magnesium stearate</u>	<u>1.5 g</u>
	Total	190.0 g

The medicament, lactose and corn starch were mixed with an alcohol solution of polyvinylpyrrolidone and granulated by kneading according to the wet granulation method, followed by drying to be formed into granules.

Subsequently, magnesium stearate and crystalline cellulose were added to the granules and the mixture is compressed to obtain tablets of 8 mm in diameter and 190 mg in weight.


Example 2

(Injection)

(+)-Cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate (10 g) was dissolved in 2 liter of distilled water for injection. The solution was filtered through a membrane filter with a pore size of 0.22 μ m, and is poured into ampoules under sterilization conditions each in 2 ml and sealed to give ampoules for injection.

CLAIMS:

1. The use of an 8-chloro-1,5-benzothiazepine derivative represented by the formula:



15 wherein R¹, R², R³ and R⁴ each represent alkyl groups having from 1 to 6 carbon atoms, or a pharmaceutically acceptable salt thereof, for preparing a prophylactic or curing medicament for arteriosclerosis.

20 2. The use according to claim 1, wherein the compound to be used is (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepine-4(5H)-one or a pharmaceutically acceptable salt thereof.

30 3. The use according to claim 1 or claim 2, wherein said pharmaceutically acceptable acid addition salt is one selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, phosphate oxalate, fumarate, tartarate and methanesulfonate thereof.

35 4. The use according to claim 1 or claim 2, wherein said pharmaceutically acceptable acid addition salt is maleate.

TIMED: 26/02/92 14:35:37

PAGE: 1

REGISTER ENTRY FOR GB2190587

Form 1 Application No GB8711752.9 filing date 19.05.1987

Priority claimed:

23.05.1986 in Japan - doc: 61119928

Title PROPHYLACTIC AND CURING COMPOSITION FOR ARTERIOSCLEROSIS

Applicant/Proprietor

TANABE SEIYAKU CO LTD, Incorporated in Japan, No 21 Dosho-machi 3-chome,
Higashi-ku, Osaka-shi, Osaka-fu, Japan [ADP No. 00758987001]

Inventors

HITOSHI IWASAKI, No 27-4-506 Kohoku 6-chome, Adachi-ku, Tokyo-to, Japan
[ADP No. 03271046001]

KITAMURA KITAMURA, No 440-2-19-403 Oaza-Tajima, Urawa-shi, Saitama-ken,
Japan [ADP No. 03939089001]

AKIO OHTANI, No 1-14-20 Nishikicho, Warabi-shi, Saitama-ken, Japan
[ADP No. 03939097001]

Classified to

A5B U1S

A61K

Address for Service

BOULT WADE & TENNANT, 27 Funnival Street, London, EC4A 1PQ, United Kingdom
[ADP No. 00000042001]

Publication No GB2190587 dated 25.11.1987

Patent Granted with effect from 17.01.1990 (Section 25(1)) with title
PROPHYLACTIC AND CURING COMPOSITION FOR ARTERIOSCLEROSIS

29.03.1989 Notification of change of Applicant/Proprietor address of
TANABE SEIYAKU CO LTD, Incorporated in Japan, No 21 Dosho-machi
3-chome, Higashi-ku, Osaka-shi, Osaka-fu, Japan [ADP No. 00758987001]

to

TANABE SEIYAKU CO LTD, Incorporated in Japan, 2-10, Dosho-machi
3-chome, Chuo-ku, Osaka, Japan [ADP No. 00758987003]
dated 21.03.1989. Official evidence filed on GB2190587

Entry Type 7.3 Staff ID. JB1 Auth ID. F20

**** END OF REGISTER ENTRY ****

DABO-01
FG

OPTICS -- PATENTS

26/02/92 14:37:04
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER GB2190587 ✓

PROPRIETOR(S)

Tanabe Seiyaku Co Ltd, Incorporated in Japan, 2-10, Doshomachi
3-chome, Chuo-ku, Osaka, Japan

DATE FILED 19.05.1987 ✓

DATE GRANTED 17.01.1990 ✓

DATE NEXT RENEWAL DUE 19.05.1992

DATE NOT IN FORCE

DATE OF LAST RENEWAL 26.04.1991

YEAR OF LAST RENEWAL 05

STATUS PATENT IN FORCE ✓